Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analyst Outlook Dims for Exelon Shares

Felix Baarz by Felix Baarz
October 25, 2025
in Analysis, Earnings, Energy & Oil
0
Exelon Stock
0
SHARES
17
VIEWS
Share on FacebookShare on Twitter

Exelon faces mounting pressure from market analysts as downward revisions to earnings forecasts and cautious institutional sentiment weigh on the utility stock. Recent developments have created headwinds for the company’s share performance ahead of its upcoming quarterly report.

Earnings Estimates Adjusted

Financial research firm Zacks Research revised its earnings outlook for Exelon downward last Friday. The firm now anticipates full-year 2025 earnings of $2.65 per share, a slight reduction from its previous projection of $2.67. This updated forecast places Zacks just marginally above the consensus estimate of $2.64 per share among market analysts.

Institutional Skepticism Persists

Morgan Stanley maintained its “Equal-Weight” rating on Exelon shares, signaling continued caution toward the utility company. This positioning reflects the investment bank’s restrained outlook for the stock’s near-term performance.

Market activity reflected this tempered sentiment, with Exelon shares declining 1.06 percent to close at $47.60 on Thursday. The downward trend continued through Friday’s trading session, extending the stock’s recent weakness.

Should investors sell immediately? Or is it worth buying Exelon?

Quarterly Performance Provides Mixed Signals

While Exelon surpassed earnings expectations in the second quarter with $0.39 per share—$0.02 above analyst predictions—the company reported revenue of $5.43 billion that fell short of market expectations. Despite this mixed performance, management reaffirmed their full-year guidance range of $2.64 to $2.74 per share.

Looking further ahead, analysts have established quarterly projections for future periods:
* Q4 2025 Forecast: $0.65 EPS
* Q2 2026 Forecast: $0.43 EPS
* Q3 2026 Forecast: $0.75 EPS

Technical Position and Upcoming Catalyst

Exelon shares are currently trading around their 50-day moving average of $44.89, remaining substantially below the 52-week high of $48.51. The stock’s performance suggests investors are awaiting clearer signals about the company’s ability to meet its annual targets.

All eyes now turn to November 4th, when Exelon will report third-quarter 2025 results. This announcement represents a critical test for the company to demonstrate its capacity to counter the recent downward revisions to earnings projections and restore investor confidence.

Ad

Exelon Stock: Buy or Sell?! New Exelon Analysis from March 25 delivers the answer:

The latest Exelon figures speak for themselves: Urgent action needed for Exelon investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Exelon: Buy or sell? Read more here...

Tags: Exelon
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Take-Two Stock
Earnings

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Next Post
IAC/InterActiveCorp Stock

Mixed Signals for IAC Stock as Conflicting Trends Emerge

iShares MSCI World ETF Stock

MSCI World ETF Rides AI Wave to Impressive Returns

Crane Company Stock

Crane Company Faces Pivotal Week with Q3 Earnings Release

Recommended

BigBearai Holdings Stock

BigBear.ai Faces Critical Test as Revenue Plummets and Losses Mount

6 months ago
D-Wave Quantum Stock

D-Wave Quantum: CFO’s Multi-Million Dollar Exit Amidst Major Capital Raise

4 months ago
Brightcove Stock

Bending Spoons Forges AI-Powered Streaming Future with Brightcove at the Core

6 months ago
Microsoft Stock

Microsoft Faces Critical Earnings Test Amid AI Expectations

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

Trending

Bionxt Solutions Stock
Healthcare

BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents

by SiterGedge
March 25, 2026
0

BioNxt Solutions has formally initiated the commercial phase for its sublingual drug delivery platform, marking a significant...

Take-Two Stock

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

March 25, 2026
Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNxt Solutions Enters Pivotal Commercial Phase with Key Patents
  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com